XenoPort (XNPT) is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s nutrient transport mechanisms to improve the therapeutic benefits of existing drugs.
Horizant is XenoPort’s first approved product. GlaxoSmithKline holds commercialization rights and certain development rights for gabapentin enacarbil in the United States. Gabapentin enacarbil is also being developed in partnership with Astellas Pharma Inc. for the potential treatment of Restless Legs Syndrome in Japan. If approved in Japan, gabapentin enacarbil would be marketed under a different trade name.
XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort’s pipeline of product candidates includes potential treatments for patients with neuropathic pain, spasticity and Parkinson’s disease. XenoPort’s product candidates were discovered and developed by XenoPort utilizing its patented Transported Prodrug technology. Except for gabapentin enacarbil, XenoPort owns rights to all of its product candidates.
XNPT Investor Highlights:
Announced along with GlaxoSmithKline that the FDA has approved Horizant Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults.
As of December 31, 2010, XenoPort had cash and cash equivalents and short-term investments of $108.6 million.
Announced plans to initiate Phase 3 development of AP as a potential treatment of spasticity in multiple sclerosis (MS) patients.
Initiated a Phase 2 randomized, double-blind, crossover clinical trial in patients with Parkinson’s disease that is designed to evaluate safety, efficacy and pharmacokinetics of XenoPort’s new bi-layer formulation of XP21279 versus Sinemet.
SciClone Pharmaceuticals (SCLN) is a U.S. specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. The Company is focused on continuing sales growth and executing a clinical development strategy with prudently managed costs. ZADAXIN® (thymalfasin) is approved in over 30 countries for the treatment of hepatitis B (HBV), as a vaccine adjuvant, for the treatment of hepatitis C (HCV), and certain cancers.
SciClone is evaluating SCV-07 in a phase 2b trial to modify the course of oral mucositis in patients with head and neck cancer. The Company also has exclusive commercialization and distribution rights in China to a novel treatment for advanced liver cancer, DC Bead®, which is already approved in approximately 40 countries worldwide, including the U.S. and several countries in Europe. DC Bead is currently under review by regulatory agencies in China.
Additionally, SciClone owns exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm® in China, including Hong Kong and Macau, and Vietnam. The Company intends to seek regulatory approval for the product, commonly used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery, in these markets.
SCLN Investor Highlights:
Revenues for the fourth quarter of 2010 grew to $23.6 million, or an increase of 30% compared to revenues of 18.1 million in the fourth quarter of 2009.
Net income for the fourth quarter of 2010 was $3.8 million or $0.08 per share on a basic and diluted basis, compared with a net income of $2.4 million or $0.05 per share, on both a basic and diluted basis, for the same period of 2009.
For the year ended December 31, 2010, total revenues grew to $85.1 million, or an 18% increase, compared with revenues of $72.4 million for the year ended December 31, 2009.
For the year ended December 31, 2010, net income was $21.1 million, or $0.44 and $0.43 per share on a basic and diluted basis, respectively, compared with a net income of $11.9 million or $0.26 and $0.25 per share on a basic and diluted basis for the same period in 2009.
Announced in January the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.
Vaalco Energy (EGY) is an independent energy company, engages in the acquisition, exploration, development, and production of crude oil and natural gas. It owns producing properties, as well as conducts exploration activities as an operator of consortiums internationally in Gabon and Angola, and as a non-operator in the British North Sea.
The company also has minor interests in the Texas and Louisiana Gulf Coast area. It owns a 30.35% interest in the exploration acreage within the Etame Marin block; a 28.1% interest in the development areas surrounding the Etame, Avouma, South Tchibala, and Ebouri fields; a 100% working interest in the Mutamba Iroru block onshore Gabon; and a 40% working interest in the 1.4 million acre Block 5 offshore Angola.
EGY Investor Highlights:
Announced that the Company has been informed that the strike in Gabon by the National Organisation of Oil Employees (ONEP), which began at midnight, March 31, 2011, has ended. VAALCO expects to resume full production offshore Gabon within 24 hours. Daily gross production in the Etame Marin block offshore Gabon has been recently averaging approximately 23,500 barrels of oil per day.
For the 2010 fourth quarter, VAALCO reported net income attributable to VAALCO of $8.9 million, or $0.15 per diluted share, compared to net income attributable to VAALCO of $2.2 million, or $0.04 per diluted share, for the comparable period in 2009.
Fourth quarter 2010 revenues were $38.2 million compared to $32.6 million in the fourth quarter of 2009.
For the year ended December 31, 2010, VAALCO reported a net income attributable to VAALCO of $37.3 million, or $0.65 per diluted share, compared to a net loss attributable to VAALCO of $7.9 million, or ($0.14) per diluted share, for the year ended December 31, 2009.
Cash on hand of $81 million with no debt.
To learn more about these Companies visit Smallcapreview.com/.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has not been been compensated by any of the above mentioned companies.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. A news service of SCR, 2312 Healy Dr., Winston-Salem, NC 27107. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play.